Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MISSION PHARMACAL's URINARY ALKALINIZER IS "APPROVABLE"

Executive Summary

MISSION PHARMACAL's URINARY ALKALINIZER IS "APPROVABLE" for use in the prevention of uric acid kidney stones, calcium oxalate kidney stones, and calcium phosphate kidney stones. The product will be indicated both for the prevention of stones in patients with a urinary condition likely to cause such stones and for the prevention of stone reformation in patients who have previously had stones. The product was given orphan drug status by FDA during 1984. FDA designated the drug "approvable" on July 26. Urocit-K will be Mission's third orphan approval in three years. FDA approved two other kidney products, Calcibind and Lithostat, in 1982 and 1983, respectively. Both Urocit-K and Calcibind were developed by University of Texas' Dr. Charles Pak. Mission said it expects FDA to approve the final labeling of the drug within the next few weeks and has started booking orders. The firm said that the price of the Urocit-K gotassium citrate) will be $42.50 plus a $2.50 handling charge for six bottles of 100 tabs. The proposed dosage recommendation is 4 tabs three times a day.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel